Tag:

Goldman Sachs

Latest Headlines

Latest Headlines

Goldman Sachs sinks $20M into India devicemaker

Goldman Sachs is the latest multinational to see promise in India's surging medical tech industry. The global investment bank invested about $20 million in BPL Medical Technologies to help the medical device and instrument company's expansion plans.

T2 reels in $40M Series E for Candida assay trial and launch

T2 Biosystems pulled in a whopping $40 million Series E funding round to support clinical testing and a commercial launch of the company's Candida infection rapid diagnostic assay.

No breakup for J&J? Goldman analyst says 'Sell'

Goldman Sachs analyst Jami Rubin can be tough to please. Particularly for companies that aren't jazzed about the idea of splitting themselves into smaller pieces. Hear that, Johnson & Johnson ($JNJ)?

AstraZeneca entices Roche exec to take on CEO challenge

AstraZeneca turned heads today with an unexpectedly intriguing CEO choice: Roche's Pascal Soriot, who's been the Swiss drugmaker's COO and pharma chief since 2010. Within hours, Soriot had a full wardrobe of expectations to try on.

Dissatisfied with bids, Warner Chilcott opts for $1B dividend

No one made an offer Warner Chilcott ($WCRX) couldn't refuse. So the Irish drugmaker says it's not selling itself after all. Instead, it will spend $1 billion on a $4-per-share dividend, presumably as a consolation prize for shareholders.

J&J should split itself three ways, Goldman analyst says

As Goldman Sachs analyst Jami Rubin sees it, there's another major drugmaker whose whole is worth less than the sum of its parts. This time, it's Johnson & Johnson--and Rubin figures it would be worth more split three ways.

ICD market has hit bottom, rebound to follow

With the wrap-up of the Heart Rhythm Society meeting in Boston last week, one of the major investment bank's came away with an encouraging message: The market for implantable cardioverter defibrillators has hit bottom.

Insider trading investigation eyes Abbott/Advanced Medical Optics deal

An ongoing insider trading investigation focused on Abbott Labs' $3 billion acquisition of Advanced Medical Optics in 2009 is getting extremely juicy.

Goldman predicts setbacks for Genzyme

Goldman Sachs added Genzyme to its Americas conviction sell list, saying that manufacturing setbacks at one of its plants may impair long-term growth at the company, and a near-term shortage of its

Expecting drama, Goldman upgrades Pfizer

Add Goldman Sachs to the list of market-watchers who predict dramatic action from Pfizer--and soon. The investment bank took Pfizer off its "Americas Sell" list, which amounts to an upgrade to